| Literature DB >> 22907368 |
Laurence Renaut1, Céline Monnet, Olivier Dubreuil, Ouafa Zaki, Fabien Crozet, Khalil Bouayadi, Hakim Kharrat, Philippe Mondon.
Abstract
As a growing number of therapeutic antibodies are developed, robust methods to efficiently improve the affinity and/or specificity of antibody candidates are needed. Here we describe our powerful platform that combines scFv affinity maturation and IgG high-throughput screening. After creating diversity with our random mutagenesis technology (MutaGen™), the scFv libraries are fully cleaned using a fusion system introducing the beta-lactamase gene to select in-frame and stop codon free variants on the basis of ampicillin resistance. The high-quality scFv libraries thereby constructed are then selected on the target in vitro using phage display technology. Contrary to standard procedures, instead of producing a limited number of affinity matured scFv as IgG molecules, we developed a cloning system to directly transfer the entire pool of selected scFv into an IgG expression vector permitting rapid IgG small-scale production (96 wells) in mammalian cells. Our integrated process allows us to generate high-quality scFv libraries and test numerous IgG variants, increasing the chances to select the best therapeutic antibody candidate.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22907368 DOI: 10.1007/978-1-61779-974-7_26
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745